Zenas BioPharma (ZBIO) Revenue (2023 - 2026)

Zenas BioPharma (ZBIO) posted quarterly Revenue of $10.0 million for Q1 2025, up 100.0% quarter-over-quarter from $5.0 million in Q4 2024.

Zenas BioPharma (ZBIO) Revenue (2023 - 2026) Analysis & Trends

Zenas BioPharma's Revenue history runs 3 years deep, the most recent figure standing at $10.0 million for Q1 2025.

In Q1 2025, Revenue changed N/A year-over-year to $10.0 million; the TTM figure through Dec 2025 stood at $10.0 million (up 100.0% YoY), while the FY2025 annual figure was $10.0 million, up 100.0% from the prior year.
Revenue for Q1 2025 stood at $10.0 million, up from $5.0 million in the prior quarter.
The five-year high for Revenue was $50.0 million in Q3 2023, with the low at $5.0 million in Q4 2024.
The 3-year median for Revenue is $10.0 million (2025), against an average of $21.7 million.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	3.33 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	4.29 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	1.56 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.71 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	3,001.92
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	674.14 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	1.29 Bn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	425.49 Mn
10	Zenas BioPharma	1.87 Bn	748.44 Mn	-	1.00 Mn

Download Data